Sara Marinelli

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/188100/sara-marinelli-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 papers	5,302 citations	22 h-index	45 g-index
45 ext. papers	6,186 ext. citations	7.1 avg, IF	4.03 L-index

#	Paper	IF	Citations
38	CXCR2 increases in ALS cortical neurons and its inhibition prevents motor neuron degeneration in vitro and improves neuromuscular function in SOD1G93A mice. *Neurobiology of Disease*, **2021**, 160, 105538	7.5	0
37	Activation of skeletal muscle-resident glial cells upon nerve injury. *JCI Insight*, **2021**, 6,	9.9	6
36	Sexually Dimorphic Immune and Neuroimmune Changes Following Peripheral Nerve Injury in Mice: Novel Insights for Gender Medicine. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
35	Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. *Acta Neuropathologica*, **2021**, 142, 537-564	14.3	1
34	Impact of caloric restriction on peripheral nerve injury-induced neuropathic pain during ageing in mice. *European Journal of Pain*, **2020**, 24, 374-382	3.7	4
33	Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice. *Toxins*, **2020**, 12,	4.9	5
32	Very Early Involvement of Innate Immunity in Peripheral Nerve Degeneration in SOD1-G93A Mice. *Frontiers in Immunology*, **2020**, 11, 575792	8.4	3
31	Innovative mouse model mimicking human-like features of spinal cord injury: efficacy of Docosahexaenoic acid on acute and chronic phases. *Scientific Reports*, **2019**, 9, 8883	4.9	7
30	Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. *Nature Cell Biology*, **2018**, 20, 917-927	23.4	100
29	Botulinum Toxin B Affects Neuropathic Pain but Not Functional Recovery after Peripheral Nerve Injury in a Mouse Model. *Toxins*, **2018**, 10,	4.9	7
28	Effects of caloric restriction on neuropathic pain, peripheral nerve degeneration and inflammation in normometabolic and autophagy defective prediabetic Ambra1 mice. *PLoS ONE*, **2018**, 13, e0208596	3.7	14
27	TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. *Nature Communications*, **2017**, 8, 15292	17.4	117
26	Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain. *European Journal of Pharmacology*, **2016**, 791, 377-388	5.3	43
25	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
24	17beta-estradiol counteracts neuropathic pain: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. *Scientific Reports*, **2016**, 6, 18980	4.9	31
23	Dataset of botulinum toxin A influence on interleukins under neuropathy. *Data in Brief*, **2016**, 9, 1020-1023	2.1	2
22	Effects of age-related loss of P/Q-type calcium channels in a mice model of peripheral nerve injury. *Neurobiology of Aging*, **2015**, 36, 352-64	5.6	5

21	D-aspartate modulates nociceptive-specific neuron activity and pain threshold in inflammatory and neuropathic pain condition in mice. *BioMed Research International*, **2015**, 2015, 905906	3	19
20	Schwann cell autophagy counteracts the onset and chronification of neuropathic pain. *Pain*, **2014**, 155, 93-107	8	61
19	M2 receptors exert analgesic action on DRG sensory neurons by negatively modulating VR1 activity. *Journal of Cellular Physiology*, **2014**, 229, 783-90	7	9
18	Higher pain perception and lack of recovery from neuropathic pain in females: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. *Pain*, **2014**, 155, 388-402	8	58
17	ProNGFNGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. *Cell Death and Differentiation*, **2013**, 20, 1017-30	12.7	51
16	Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and □opioid receptor expression in neuropathic mice. *Brain, Behavior, and Immunity*, **2013**, 32, 40-50	16.6	38
15	Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice. *Brain, Behavior, and Immunity*, **2012**, 26, 489-99	16.6	21
14	Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. *PLoS ONE*, **2012**, 7, e32212	3.7	5
13	Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice. *PLoS ONE*, **2012**, 7, e37555	3.7	46
12	The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. *PLoS ONE*, **2012**, 7, e47977	3.7	96
11	Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice. *Translational Psychiatry*, **2012**, 2, e155	8.6	38
10	The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. *Neuroscience*, **2011**, 175, 358-66	3.9	54
9	Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. *PLoS ONE*, **2011**, 6, e17321	3.7	73
8	In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V. *Biochemical and Biophysical Research Communications*, **2010**, 391, 824-9	3.4	38
7	Short- but not long-lasting treadmill running reduces allodynia and improves functional recovery after peripheral nerve injury. *Neuroscience*, **2010**, 168, 273-87	3.9	78
6	Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. *Neuroscience*, **2010**, 171, 316-28	3.9	66
5	The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating mu-opioid receptors. *Pain*, **2009**, 145, 219-29	8	22
4	The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 2985-90	11.5	100

3	Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. *Neuroscience*, **2007**, 145, 1-4	3.9	80
2	Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. *Brain Research*, **2006**, 1082, 124-31	3.7	61
1	Pain sensitivity in mice lacking the Ca(v)2.1alpha1 subunit of P/Q-type Ca2+ channels. *Neuroscience*, **2006**, 142, 823-32	3.9	51